Logo

Steven Averbuch

Jul 03, 2019

Steven Averbuch has joined Caris Life Sciences' scientific advisory board. Averbuch recently retired from the role of vice president and head of precision medicine in the translational medicine division of R&D at Bristol-Myers Squibb. During his tenure, Averbuch spearheaded the Pharmacodiagnostics Center of Excellence, which led to the application of BMS' precision medicine strategy across all therapeutic areas. Prior to this, Averbuch oversaw corporate-wide strategic initiatives for translational and targeted medicine at BMS. He also served as head of early global clinical research at the company. Averbuch also previously held leadership roles with Merck Research Laboratories and AstraZeneca, and held academic appointments at Mount Sinai School of Medicine and the US Public Health Service School of Medicine.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.